Clinical trials: Degenerative Conditions, Neurologic
Parkinson's Disease
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
The purpose of this study is to the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa…
- Trial name
- NCT02774564
- Testing
- BIA 3-202, Sinemet®
- Where
- Portugal
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer Disease
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
This clinical study is designed as a multi-center, randomized, double-blind, placebo-controlled, parallel design, prospective, phase II clinical trial.
- Trial name
- NCT03184467
- Testing
- Normal Saline 0.9%, GV1001 0.56 mg, GV1001 1.12 mg
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- GemVax & Kael
AMN, AMN Gene Mutation
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
This is a Phase 1/2 randomized, blinded, dose-escalation study to evaluate the safety and efficacy of intrathecal (IT) administration of SBT101, a recombinant adeno-associated virus serotype 9 (AAV9) containing a functional copy…
- Conditions
- AMN, AMN Gene Mutation, X-ALD
- Trial name
- PROPEL (NCT05394064)
- Testing
- SBT101 Treatment
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 9 people
- Sponsor
- SwanBio Therapeutics, Inc.
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
- Trial name
- NCT02162264
- Testing
- Donepezil Hydrochloride
- Where
- Japan
- Volunteers
- 8,662 people
- Sponsor
- Eisai Co., Ltd.
Parkinson's Disease
BIIB014 Phase 2a Monotherapy
To assess the preliminary safety and tolerability of multiple oral doses of BIIB014 in subjects with early PD.
- Trial name
- NCT00451815
- Testing
- active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.
- Sponsor
- Biogen
Alzheimer Disease
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565291
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
Parkinson´s Disease
Rostock International Parkinson's Disease Study (ROPAD)
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the…
- Trial name
- ROPAD (NCT03866603)
- Where
- 110 sites in United States, Albania and 13 more
- Volunteers
- 20,112 people
- Sponsor
- CENTOGENE GmbH Rostock
Alzheimer Disease
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
The objective of this study is to evaluate the safety and efficacy of ID1201 in patients with mild Alzheimer's disease
- Trial name
- NCT03363269
- Testing
- ID1201
- Where
- 20 sites in South Korea
- Volunteers
- 116 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Dementia With Lewy Bodies (DLB)
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies
The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).
- Trial name
- NCT00598650
- Testing
- E2020
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males
To assess the safety and tolerability of ascending single oral doses of SAM-531, an investigational drug, in healthy Japanese male subjects.
- Trial name
- NCT00479297
- Testing
- SAM-531
- Volunteers
- 72 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Shoulder Fractures, Shoulder Arthritis Osteoarthritis
Zimmer Biomet Shoulder Arthroplasty PMCF Study
This is a multicenter, prospective, non-controlled post market surveillance study. The objectives of this study are to confirm the safety, performance, and clinical benefits of the Zimmer Biomet Shoulder Arthroplasty systems in…
- Conditions
- Shoulder Fractures, Shoulder Arthritis Osteoarthritis, Shoulder Injury, Shoulder Pain
- Trial name
- NCT06920459
- Testing
- Alliance™ Glenoid
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 50 people
- Sponsor
- Zimmer Biomet
Myasthenia Gravis
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.
- Trial name
- NCT04226170
- Testing
- DAS-001
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- DAS-MG, Inc
Neurodegenerative Diseases
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants
This is a first in human study to determine the safety, tolerability and pharmacokinetics of ONO-2808 in healthy adult participants.
- Trial name
- NCT04578028
- Testing
- ONO-2808
- Where
- United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer Disease
ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease
The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of AD, as compared to no stimulation (OFF), by measuring baseline…
- Trial name
- NCT03622905
- Testing
- DBS-f On, DBS Off
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 74 people
- Sponsor
- Functional Neuromodulation Ltd
Generalized Myasthenia Gravis
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.
- Trial name
- ADAPT Jr (NCT04833894)
- Testing
- Efgartigimod IV
- Where
- 25 sites in United States, Austria and 10 more
- Volunteers
- 15 people
- Sponsor
- argenx
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant
Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation
The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.
- Conditions
- Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
- Trial name
- NCT06140329
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 1 people
- Sponsor
- PYC Therapeutics
Parkinson's Disease
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under…
- Trial name
- NCT03887884
- Testing
- CVT-301, Sinemet
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acorda Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.